Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267
|
CN |
|
Nyxoah SA
XBRU:NYXH
|
BE |
|
R
|
Ritamix Global Ltd
HKEX:1936
|
MY |
|
PEXA Group Ltd
ASX:PXA
|
AU |
|
C
|
China Shineway Pharmaceutical Group Ltd
HKEX:2877
|
CN |
|
Beijing LongRuan Technologies Inc
SSE:688078
|
CN |
|
Ranger Energy Services Inc
NYSE:RNGR
|
US |
|
Hexagon AB
STO:HEXA B
|
SE |
|
Sorrento Therapeutics Inc
OTC:SRNE
|
US |
|
B
|
Bajel Projects Ltd
NSE:BAJEL
|
IN |
|
bebe stores inc
OTC:BEBE
|
US |
|
Gufic Biosciences Ltd
NSE:GUFICBIO
|
IN |
Bankruptcy Probability
Hunan Er-Kang Pharmaceutical Co Ltd's probability of bankruptcy is hidden . The solvency score is hidden .
We take all the information about a company's solvency (such as how easily a company can pay interest on its outstanding debt, how much cash it has, the amount of debt, and more) and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Hunan Er-Kang Pharmaceutical Co Ltd Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CN |
H
|
Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267
|
7.6B CNY |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
847.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
576.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Hunan Er-Kang Pharmaceutical Co Ltd's probability of bankruptcy is hidden .
The probability of bankruptcy is estimated using credit risk models that assess its financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Hunan Er-Kang Pharmaceutical Co Ltd has total debt of 350.2m CNY. This includes both short-term (321.5m CNY) and long-term (28.7m CNY) debt.
You can find a full breakdown on its Balance Sheet.
